Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Transabdominal Amnioinfusion Treatment of Severe Oligohydramnios in Preterm Premature Rupture of Membranes at Less than 26 Gestational Weeks

De Santis M.a · Scavo M.a · Noia G.a · Masini L.a · Piersigilli F.b · Romagnoli C.b · Caruso A.a

Author affiliations

Departments of aObstetrics and Gynecology, and bPediatrics, Catholic University of Sacred Heart, Rome, Italy

Related Articles for ""

Fetal Diagn Ther 2003;18:412–417

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: October 29, 2002
Accepted: November 12, 2002
Published online: October 23, 2003
Issue release date: November – December

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT

Abstract

Objective: To evaluate the efficacy of transabdominal amnioinfusion on feto-neonatal and maternal morbidity and feto-neonatal mortality. Methods: We studied 71 patients with preterm premature rupture of membranes (pPROM) at <26 weeks of gestational age. Thirty-four patients were managed expectantly and 37 underwent serial transabdominal amnioinfusion with saline every 7 days in case of persistent oligohydramnios. Results: Latency period pPROM delivery, week of delivery (26.0 vs. 22.4, p < 0.001), neonatal weight (922 vs. 602, p < 0.01) and the percentage of intrauterine fetal survival were higher in treated than in control groups (64.8 vs. 32.3%, p < 0.01). In amnioinfusion-treated patients, we did not note a higher rate of complications from infection during both pregnancy and puerperium. In the amnioinfusion group, fluid loss within 6 h after infusion is the main variable in predicting pulmonary hypoplasia and neonatal survival. Conclusions: Our data suggest that amnioinfusion seems to be a low fetal and maternal risk technique that modifies the natural history of pPROM, improving fetal intrauterine stay and survival.

© 2003 S. Karger AG, Basel


References

  1. Nimrod C, Varela-Gittings F, Machin G, Campbell D, Wesenberg R: The effect of very prolonged membrane rupture on fetal development. Am J Obstet Gynecol 1984;148:540–543.
  2. Taylor JO, Garite TJ: Premature rupture of membranes before fetal viability. Obstet Gynecol 1984;64:615.
  3. Moretti M, Sibai BM: Maternal and perinatal outcome of expectant management of premature rupture of membranes in midtrimester. Am J Obstet Gynecol 1988;159:390–396.
  4. Hadi HA, Hodson CA, Strickland D: Premature rupture of the membranes between 20 and 25 weeks’ gestation: Role of amniotic fluid in perinatal outcome. Am J Obstet Gynecol 1994;170:1139–1144.
  5. Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ: Degree of oligohydramnios and pregnancies with preterm premature rupture of the membranes. Obstet Gynecol 1985;66:162–167.
  6. Vergani P, Ghidini A, Locatelli A, Cavallone M, Ciarla I, Cappellini A, Lapinski RH: Risk factors for pulmonary hypoplasia in second-trimester premature rupture of membranes. Am J Obstet Gynecol 1994;170:1359–1364.
  7. Richards DS: Complications of prolonged PROM and oligohydramnios. Clin Obstet Gynecol 1998;41:817–826.
  8. Newton ER: Chorioamnionitis and intra-amniotic infection. Clin Obstet Gynecol 1993;36:795–808.
  9. Rotschild A: Neonatal outcome after prolonged preterm rupture of the membranes. Am J Obstet Gynecol 1990;162:46–52.
  10. Alexander JM, Cox SM: Clinical course of premature rupture of the membranes. Semin Perinatol 1996;20:369–374.
  11. Fisk NM, Ronderos-Dumit D, Soliani A, Nicolini U, Vaughan J, Rodeck C: Diagnostic and therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991;78:270–277.
  12. Garzetti GG, Ciavattini A, De Cristofaro S, La Marca N, Arduini D: Prophylactic transabdominal amnioinfusion in oligohydramnios for preterm premature rupture of membranes: Increase of amniotic fluid index during latency period. Gynecol Obstet Invest 1997;44:249–254.
  13. Vergani P, Locatelli A, Strobelt N, Mariani S, Cavallone M, Arosio P, Ghidini A: Amnioinfusion for prevention of pulmonary hypoplasia in second trimester rupture of membranes. Am J Perinatol 1997;14:325–329.
  14. Locatelli A, Vergani P, Di Pirro G, Doria V, Biffi A, Ghidini A: Role of amnioinfusion in the management of premature rupture of the membranes at <26 weeks’ gestation. Am J Obstet Gynecol 2000;183:878–882.
  15. Imanaka M, Ogita S, Sugawa T: Saline solution amnioinfusion for oligohydramnios after premature rupture of the membranes. Am J Obstet Gynecol 1989;161:102–106.
  16. Askenazi SS, Perlman M: Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis. Arch Dis Child 1979;54:614–618.
  17. Leonidas JC, Bhan I, Beatty EC: Radiographic chest contour and pulmonary air leaks in oligohydramnios-related pulmonary hypoplasia (Potter’s syndrome). Invest Radiol 1982;17:6–10.
  18. Papille LA, Burstein J, Burstein R, Koffer H: Incidence and evaluation of subependymal and intraventricular haemorrhage: A study of infants with birth weight less than 1,500 g. J Pediatr 1978;92:529–534.
  19. De Vries LS, Eken P, Dubowitz LMS: The spectrum of leukomalacia using cranial ultrasound. Behav Brain Res 1992;49:1–6.
  20. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respiratory therapy of hyaline membrane disease: Bronchopulmonary dysplasia. N Engl J Med 1967;276:357–365.

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: October 29, 2002
Accepted: November 12, 2002
Published online: October 23, 2003
Issue release date: November – December

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 5

ISSN: 1015-3837 (Print)
eISSN: 1421-9964 (Online)

For additional information: https://www.karger.com/FDT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.